Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1973 1
1975 1
1976 1
1996 1
1997 2
1998 4
1999 6
2000 6
2001 12
2002 6
2003 14
2004 23
2005 13
2006 20
2007 46
2008 81
2009 79
2010 84
2011 120
2012 143
2013 154
2014 144
2015 113
2016 129
2017 119
2018 149
2019 166
2020 233
2021 258
2022 230
2023 195
2024 219
2025 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,143 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD. Bajorin DF, et al. Among authors: shariat sf. N Engl J Med. 2021 Jun 3;384(22):2102-2114. doi: 10.1056/NEJMoa2034442. N Engl J Med. 2021. PMID: 34077643 Free PMC article. Clinical Trial.
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S; ESMO Guidelines Committee. Electronic address: [email protected]. Powles T, et al. Among authors: shariat sf. Ann Oncol. 2022 Mar;33(3):244-258. doi: 10.1016/j.annonc.2021.11.012. Epub 2021 Nov 30. Ann Oncol. 2022. PMID: 34861372 Free article. No abstract available.
Epidemiology and risk factors of urothelial bladder cancer.
Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y. Burger M, et al. Among authors: shariat s. Eur Urol. 2013 Feb;63(2):234-41. doi: 10.1016/j.eururo.2012.07.033. Epub 2012 Jul 25. Eur Urol. 2013. PMID: 22877502 Review.
Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Compérat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, Lotan Y, Palou J, Gontero P, Babjuk M, Witjes JA, Kamat AM, Roupret M, Shariat SF, Pradere B; European Association of Urology–Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Laukhtina E, et al. Among authors: shariat sf. Eur Urol Oncol. 2021 Dec;4(6):927-942. doi: 10.1016/j.euo.2021.10.003. Epub 2021 Nov 6. Eur Urol Oncol. 2021. PMID: 34753702 Free article. Review.
Urothelial carcinoma.
Merseburger AS, Shariat SF. Merseburger AS, et al. Among authors: shariat sf. World J Urol. 2011 Aug;29(4):405-7. doi: 10.1007/s00345-011-0733-9. Epub 2011 Jul 21. World J Urol. 2011. PMID: 21779833 No abstract available.
Reply by Authors.
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Wenzel M, et al. Among authors: shariat sf. J Urol. 2021 Jul;206(1):79. doi: 10.1097/JU.0000000000001695.03. Epub 2021 Apr 6. J Urol. 2021. PMID: 33820427 No abstract available.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Powles T, et al. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. Lancet Oncol. 2020. PMID: 32971005 Clinical Trial.
2,143 results